Suicide Gene Therapy : Methods and Reviews

1. Introduction to the Background, Principles, and State of
the Art in Suicide Gene Therapy
Niculescu-Duvaz, Ion; Springer, Caroline J.
pp. 1-28
2. Introduction to Vectors for Suicide Gene Therapy
Springer, Caroline J.
pp. 29-46
3. Construction of VNP20009: A Novel, Genetically Stable
Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for
Parenteral Administration in Humans
Low, Kenneth Brooks; Ittensohn, Martina; Luo, Xiang; Zheng, Li-
Mou; King, Ivan; Pawelek, John M.; Bermudes, David
pp. 47-60
4. Nonreplicating DNA Viral Vectors for Suicide Gene Therapy:
The Adenoviral Vectors
Yamamoto, Masato; Curiel, David T.
pp. 61-70
5. Replication-Selective Oncolytic Adenoviruses
Halldén, Gunnel; Thorne, Stephen H.; Yang, Jingping; Kirn,
David H.
pp. 71-90
6. Retroviral Vectors for Suicide Gene Therapy
Porter, Colin
pp. 91-106
7. Nonviral Liposomes
Miller, Andrew D.
pp. 107-138
8. Peptide- and Polymer-Based Gene Delivery Vehicles
Brokx, Richard; Gariépy, Jean
pp. 139-160
9. Design of Prodrugs for Suicide Gene Therapy
Niculescu-Duvaz, Dan; Niculescu-Duvaz, Ion; Springer, Caroline J.
pp. 161-202
10. Cytochrome P450-Based Gene Therapies for Cancer
Chiocca, E. Antonio; Waxman, David J.
pp. 203-222
11. Tumor Sensitization to Purine Analogs by E. coli PNP
Curlee, Kimberly V.; Parker, William B.; Sorscher, Eric J.
pp. 223-246
12. Enzyme-Prodrug Systems: Carboxylesterase/CPT-11
Danks, Mary K.; Potter, Philip M.
pp. 247-262
13. Enzyme-Prodrug Systems: Thymidine Phosphorylase/5'-Deoxy-5-
Fluorouridine
Evrard, Alexandre; Ciccolini, Joseph; Cuq, Pierre; Cano, Jean-
Paul
pp. 263-278
14. Methods to Improve Efficacy in Suicide Gene Therapy
Approaches: Targeting Prodrug-Activating Enzymes
Carboxypeptidase G2 and Nitroreductase to Different Subcellular
Compartments
Schepelmann, Silke; Spooner, Robert; Friedlos, Frank; Marais,
Richard
pp. 279-302
15. Extracellular β-Glucuronidase for Gene-Directed Enzyme-
Prodrug Therapy
Brüsselbach, Sabine
pp. 303-330
16. Enhancement of Suicide Gene Prodrug Activation by Random
Mutagenesis
Kurtz, Jean-Emmanuel; Black, Margaret E.
pp. 331-344
17. Combination Suicide Gene Therapy
Uckert, Wolfgang; Salmons, Brian; Beltinger, Christian; Gü
nzburg, Walter H.; Kammertöns, Thomas
pp. 345-352
18. Immune Response to Suicide Gene Therapy
Kuriyama, Shigeki; Tsujinoue, Hirohisa; Yoshiji, Hitoshi
pp. 353-370
19. Targeting Cancer With Gene Therapy Using Hypoxia as a
Stimulus
Dachs, Gabi U.; Greco, Olga; Tozer, Gillian M.
pp. 371-388
20. Radiation-Activated Antitumor Vectors
Scott, Simon D.; Marples, Brian
pp. 389-402
21. In Vitro and In Vivo Models for Evaluation of GDEPT:
Quantifying Bystander Killing in Cell Cultures and Tumors
Wilson, William R.; Pullen, Susan M.; Hogg, Alison; Hobbs,
Stephen M.; Pruijn, Frederik B.; Hicks, Kevin O.
pp. 403-432
22. Suicide Gene Therapy in Liver Tumors
Jiao, Long R.; Havlik, Roman; Nicholls, Joanna; Jensen, Steen
Lindkaer; Habib, Nagy A.
pp. 433-450
23. Clinical Trials With GDEPT: Cytosine Deaminase and 5-
Fluorocytosine
Brown, Nicola L.; Lemoine, Nicholas R.
pp. 451-458
24. The Nitroreductase/CB1954 Enzyme-Prodrug System
Green, Nicola K.; Kerr, David J.; Mautner, Vivien; Harris, Peter
A.; Searle, Peter F.
pp. 459-478
25. Side Effects of Suicide Gene Therapy
van der Eb, Marjolijn M.; de Leeuw, Bertie; van der Eb, Alex J.;
Hoeben, Rob C.
pp. 479-490
26. Antibody-Directed Enzyme-Prodrug Therapy
Pedley, R. Barbara; Sharma, Surinder K.; Hawkins, Robert E.;
Chester, Kerry A.
pp. 491-514
27. Bioreductive Prodrugs for Cancer Therapy
Seddon, Beatrice; Kelland, Lloyd R.; Workman, Paul
pp. 515-542